High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 21, Issue 4, 1998, Pages 383-389

  Weaver, C H ^a   Schwartzberg, L ^a   Rhinehart, S ^a   West, J ^a   Zhen, B ^a   West, W H ^a   Buckner, C D ^a,b  

^a Response Oncology Inc   (United States)

^b Response Oncology Inc   (United States)

Author keywords

Autologous stem cells; High dose chemotherapy; Non Hodgkins lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031914825     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701101     Document Type: Article

References (45)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapse of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
2. Goldstone A, McMillan A, Chopra R. High-dose therapy for the treatment of non-Hodgkin's lymphoma. In: Armitage JO, Antman KH (eds). High-Dose Cancer Therapy (Pharmacology, Hematopoietins, Stem Cells). Williams & Wilkins: Baltimore, 1992, pp 662-676.
3. Romaguera J. Can we identify patients with low grade lymphoma for frontline ABMT? Leuk Lymphoma 1993; 10 (Suppl.): 9-15.
4. Salzman D, Briggs A, Vaughan W. Bone marrow transplantation for non-Hodgkin's lymphoma: a review. Am J Med Sci 1997; 313: 228-235.
5. Colombat P, Gorin NC, Lemonnier MP et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkinson's lymphomas. J Clin Oncol 1990; 8: 630-637.
6. Weisdorf DJ, Haake R, Miller WJ et al. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging. Bone Marrow Treatment 1991; 8: 135-142.
7. Gulati S, Yahalom J, Acaba L et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936-941.
8. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
9. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12: 2559-2566.
10. Horning SJ, Negrin RS, Chao NJ et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2552-2558.
11. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454-2464.
12. Schouten H, Bierman P, Vaughan W et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74: 2579-2584.
13. Freedman A, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524-2529.
14. Rohatiner A, Freedman A, Nadler L et al. Myeloblative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol 1994; 5 (Suppl. 2): 143-146.
15. Fouillard L, Gorin N, Laporte J et al. Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin's lymphoma. Eur J Haematol 1991; 46: 279-284.
16. Colombat P, Donadio D, Fouillard L et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994; 13: 157-162.
17. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
18. Johnson PWM, Price CGA, Smith T et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798-805.
19. Rohatiner A, Johnson P, Price C et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-1184.
20. Cervantes F, Shu X, McGlave P et al. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 16: 387-392.
21. Haas R, Moos M, Karcher A et al. Sequential high-dose therapy with peripheral blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685-1692.
22. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257-3262.
23. Linassier C, Fouillard L, Milpied N et al. Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional chemotherapy: a France Autogreffe study. Cancer Detect Prev 1996; 20: 11-19.
24. Stockerl-Goldstein K, Horning S, Negrin R et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 76-85.
25. Bierman P, Vose J, Anderson J et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-450.
26. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
27. Freedman A, Gribben J, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
28. The non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
29. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
30. The American Society of Clinical Oncology and American Society of Hematology recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 1990; 8: 563-564.
31. Schwartzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
32. Tutschka PJ, Copeland EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
33. Weaver CH, Schwartzberg LS, Li W et al. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. Bone Marrow Transplant 1996; 17: 715-721.
34. Green S, Weiss GR. Southwest Oncology Group standard criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
35. Crawford SW. Critical care and respiratory failure. In: Thomas ED, Forman SJ, Blume K (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, 1994, pp 513-526.
36. Shuhart MC, Myerson D, Childs BH et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood 1994; 84: 3229-3235.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
38. Santos GW, Tutschka PJ, Brookmeyer R. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
39. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
40. Copelan EA, Tutschka PJ. Marrow transplantation following busulfan and cyclophosphamide in multiple myeloma. Bone Marrow Transplant 1988; 3: 363-365.
41. Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80: 1648-1658.
42. Bensinger WI, Buckner CD, Clift RA et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10: 1492-1497.
43. Weaver CH, Bensinger WI, Appelbaum K et al. Phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
44. Schiffman K, Buckner C, Maloney D et al. High-dose busulphan, melphalan and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997 (in press).
45. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.